Luc Mathis

What if we could identify disease-associated changes before conventional testing confirms infection? That is one of the opportunities created by monitoring the volatile organic compounds — VOCs — produced as an animal's biology changes. RoboScientific's technology doesn't rely on changes in behaviour, sound, movement or production to tell us that something may be wrong. We measure the biochemical signals associated with changing health. One example is our published work investigating Campylobacter in poultry. Using RoboScientific's VOC sensing technology, we were able to distinguish VOC patterns associated with Campylobacter-negative and infected birds, with infection status independently corroborated by PCR. Importantly, the VOC data also identified a changing pattern associated with infection in samples collected ahead of the subsequent PCR-confirmed positive samples. The work was published in Scientific Reports. This is important because FARM-PROTECT is being developed to take this underlying science out of the laboratory and into commercial livestock production. Our FARM-PROTECT monitors can automatically sample poultry-house air at programmed intervals, analyse the VOC profile and provide farmers and veterinarians with earlier awareness that flock health may be changing. Ø  No handling individual birds Ø  No samples routinely sent to a laboratory. Ø  Automated monitoring of the flock environment. And Campylobacter is only one application. We are developing FARM-PROTECT as a multi-disease Poultry Health Intelligence Platform, with applications across broilers, pullets and layers — and the underlying RoboScientific technology has already been applied across pigs, dairy cattle and calves. We are now raising £1.5m growth investment to accelerate the transition from validated technology to commercial deployment. Through the Defra Farming Innovation Investor Partnership, this investment could potentially be aligned with £675,000 of grant funding, subject to final assessment and approval. If you invest in AgTech, Animal Health, biological sensing or DeepTech, I'd be very pleased to talk. #Investment #AgTech #AnimalHealth #Poultry #DiseaseDetection #VOCSensing #DeepTech #FarmingInnovation  

3

1 commentaire

Leader Strategy: Market Formation or Isolation? To continue the thought from the post: FreezeM To continue the thought from the post: http://bit.ly/4gUoEOF The reality is that production startups and unique technology companies that could ensure profitability in the BSF (Black Soldier Fly) case are either going bankrupt or are hopelessly unprofitable. There is no one willing to support the real sector. As a result, the few "stars" of this sector—scientists and top managers with invaluable practical experience—are moving en masse overseas and to Asia. Following the publication of the EU's “Nature Credits Roadmap”, the activation around the consolidation of bankrupt and unprofitable companies, and the open disregard for the critical situation by those who should defend and support the sector, it has become evident: the European insect sector, represented by a few major players, is being prepared to master the next massive financial flows. The scent of big money awakens hidden instincts. There are no illusions left. The companies that can truly change the situation are FreezeM, NRGene Ltd, Beta Bugs Limited, and Nasekomo. Today, they are at the peak of financial success. However, their strategic future depends on three key actions: 1. The Profitability Axiom The sector will not survive without scalable and accessible profitability. In the BSFL case, this is achievable only through comprehensive changes to the technological regulations, organizational approach, and, critically, genetic know-how. The main factor is larva size, which allows for a greater mass of chitinous cuticle—a key element in forming a competitive cost structure. 2. Rescuing the Golden Reserve Key players are obligated to invite unique specialists from bankrupt companies and support them with grants. These individuals are the golden reserve of ideas and expertise that can ensure the future viability and scientific progress of the entire sector. The loss of this human capital is irreversible. 3. Forming a Consumer Base If the leaders do not actively participate in forming the small consumer base for their products, no matter how "golden" their technology is, the time will come when they have no one to sell it to. Without a healthy, numerous segment of small operators, demand for advanced genetics will be limited. As is known, you cannot sell even water in a desert—there’s no one there. Conclusion FreezeM, NRGene Ltd, Beta Bugs Limited, and Nasekomo, your financial success is stable today. But the future of your sector is in your hands. You can become the locomotive that develops the entire industry, or you can remain "lonely stars" against a backdrop of market devastation. What strategy they choose remains to be seen. Good luck to everyone, and keep the faith. #LinkedIn #InsectFarming #BSF #AlternativeProtein #BlackSoldierFly #InsectProtein #AlternativeProtein #BSF (Black Soldier Fly) #BSFFarming #BlackSoldierFly #HermetiaIllucens #AnimalFeed

3

𝗣𝗵𝗼𝘀𝗽𝗵𝗮𝘁𝗮𝘀𝗲𝘀 𝗵𝗮𝘃𝗲 𝗹𝗼𝗻𝗴 𝗯𝗲𝗲𝗻 𝗱𝗶𝘀𝗺𝗶𝘀𝘀𝗲𝗱 𝗮𝘀 "𝘂𝗻𝗱𝗿𝘂𝗴𝗴𝗮𝗯𝗹𝗲" — but that's changing fast, with new phosphatase-targeted strategies now advancing into clinical development. Here's the problem: most commercial phosphatase profiling still relies on DiFMUP — a generic small-molecule substrate, not a physiologically relevant one, typically reported as a single % inhibition value per compound. That tells you that inhibition occurred — not whether it's fast or slow-binding, reversible or covalent, or how it behaves against a real substrate motif rather than a generic reporter. We built KinSight™ differently. Validated activity assays across 48 phosphatases, profiled with continuous, real-time PhosphoSens® kinetics — more than offered by other major profiling platforms, and the 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗽𝗮𝗻𝗲𝗹. And this isn't just a phosphatase-program problem. Kinase inhibitors and other enzyme-targeted therapeutics can hit phosphatases unintentionally — masking efficacy signals and introducing tox liabilities that surface late, when they're expensive to fix. https://lnkd.in/ekdu57_r

3